Takeda to withdraw sNDA for lymphoma drug Pharmaceutical Business Review Takeda Pharmaceutical and its subsidiary the Takeda Oncology company - Millennium have made decision to withdraw the supplemental new drug application (sNDA) for the use of Velcade (bortezomib) for Injection in combination with rituximab for the ... |
